Digital therapeutics developer Click Therapeutics is bolstering its focus on cardiometabolic disorders by acquiring the assets of Better Therapeutics. Better developed a FDA-authorized digital therapeutic called AspyreRx, a type 2 diabetes mobile app that uses AI to personalize treatment plans for patients. Although Better struggled to commercialize AspyreRx independently, Click sees potential in integrating the technology with their own programs. Click’s hybrid business model includes collaborating with pharmaceutical companies, and they have had success with digital therapeutics for smoking cessation and major depressive disorder. The acquisition of Better’s assets will allow Click to expand their offerings in cardiometabolic diseases and potentially improve clinical outcomes by combining digital therapy with traditional medication.
Source link
With M&A Deal, Click Therapeutics’ Digital Prospects in Metabolic Disease Get Better
